MiR-30c-5p attenuates pathological pathways such as mitogen-activated protein kinases by targeting ROCK2 [74], which presents a novel therapeutic target, miR-30c/ROCK2, in the pathogenesis of stroke. This evidence concerns the gene ROCK2 and stroke disorder.